BioSpace News Archive

The robust cloud platform will allow enhanced integration of trial management and documentation services through these new CTMS and eTMF solutions.

RareCyte, Inc. (“RareCyte” or “the Company”) a Life Sciences company creating liquid and tissue biopsy analysis platforms with emphasis on rare cell detection announced today the completion of a $22M financing from new and existing investors.

Rheos Medicines (Rheos), a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced that it has entered into a worldwide exclusive collaboration, option and license agreement with Roche to discover, develop and commercialize novel therapeutics in the field of immunometabolism.

Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the fourth quarter of 2019 on Thursday, February 6, 2020

FORMA Therapeutics, Inc., a clinical stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced the closing of $100 million Series D financing

Exelixis, Inc. (NASDAQ:EXEL) today announced a collaboration agreement with Roche to evaluate cabozantinib (CABOMETYX®), Exelixis’ small molecule inhibitor of receptor tyrosine kinases, in combination with atezolizumab (TECENTRIQ®), Roche’s PD-L1 immune checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors.

Incyte announces the appointment of Edmund P. Harrigan, M.D., as a new member of the Board of Directors, effective December 16, 2019..

Annamycin shows unusually high lung uptake and anticancer activity against lung metastases of multiple solid tumors

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President of IVERIC bio, will present an overview of the Company at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2020 at 11:30 a.m.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced details for its R&D Investor Symposium being held in San Francisco on Tuesday, January 14, 2020, from 6:30 a.m. to 8:00 a.m. Pacific Time.